Ascendis Pharma Endocrinology Division A/s

This study tested a once-weekly injection called lonapegsomatropin in 220 adults with growth hormone deficiency who had already completed a previous trial. The goal was to see if the drug remains safe and effective over a full year. Participants received the injection for 52 week…

This phase 3 trial tests a long-acting growth hormone called TransCon hGH, given as a once-weekly injection, in about 150 children with growth hormone deficiency. The study aims to see if the weekly shot is safe and helps children grow at a normal rate. All participants receive t…

This phase 3 trial tests whether a once-weekly injection of TransCon hGH works as well as daily growth hormone injections in prepubertal children with growth hormone deficiency. About 150 children who have not received growth hormone treatment before will receive either the weekl…

This phase 3 trial investigates whether a once-weekly injection of lonapegsomatropin, a long-acting growth hormone, can safely and effectively treat adults with growth hormone deficiency. The study compares the weekly drug against a placebo and a standard daily growth hormone pro…